James Kuo, MD, MBA
Chairman
Committee Served: Audit
View Bio
Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Dr. Jennifer Bath
Director
Committees Served: Finance (ad hoc)
View Bio
Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.
Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
Greg Smith
Director
Committees Served: Audit & Compensation
View Bio
Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).
Paul Andreola
Director
Committees Served: Compensation & Nomination & Finance (ad hoc)
View Bio
Paul Andreola has over 20 years of business development and financial markets experience including senior management, marketing, and communications roles for early stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and has facilitated multiple early stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of NameSilo Technologies (URL:CSE) and Ironwood Capital Corp. (TSXV: IRN.P).
Dr. Robert D. Burke
Director
Committees Served: Audit & Nomination
View Bio
Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.
Brian Lundstrom
Director
View Bio
Brian Lundstrom has over 30 years’ experience in biotech. He started his career in product and clinical development for Novo Nordisk in Europe, in 1987, prior to moving to the US for business development work. He subsequently served at OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. Mr. Lundstrom was involved in SangStat’s $600M sale and integration into Genzyme in 2003.
Since 2011, Mr. Lundstrom has established global business leadership in transgenic animals for the discovery of human, therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. Mr. Lundstrom is also the founder and CEO of Abvivo, LLC.
James Kuo, MD, MBA
Chairman
Committee Served: Audit
Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Brian Lundstrom
Director
Brian Lundstrom has over 30 years’ experience in biotech. He started his career in product and clinical development for Novo Nordisk in Europe, in 1987, prior to moving to the US for business development work. He subsequently served at OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. Mr. Lundstrom was involved in SangStat’s $600M sale and integration into Genzyme in 2003.
Since 2011, Mr. Lundstrom has established global business leadership in transgenic animals for the discovery of human, therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. Mr. Lundstrom is also the founder and CEO of Abvivo, LLC.
Dr. Jennifer Bath
Director
Committees Served: Finance (ad hoc)
Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.
Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
Greg Smith
Director
Committees Served: Audit & Compensation
Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & as well as Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd., which collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).
Paul Andreola
Director
Committees Served: Compensation & Nomination & Finance (ad hoc)
Paul Andreola has over twenty years' of business development and financial markets experience including senior management, marketing, and communications roles for early-stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and facilitated multiple early-stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of NameSilo Technologies (URL:CSE) and Ironwood Capital Corp. (TSXV: IRN.P).
Dr. Robert D. Burke
Director
Committees Served: Audit & Nomination
Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc and a PhD at the University of Alberta.